Group-based compassionate mind training for low mood and anxiety in the menopause transition: a feasibility randomized controlled trial.

Authors

Simone Saidel, Kate Robinson, Helen Donovan, Rachel Evans, Meena Khatwa, Aimee Spector

Published in

Menopause (New York, N.Y.). Jul 07, 2026. Epub Jul 07, 2026.

Abstract

The menopause transition (MT) can present with a range of biopsychosocial challenges, including peaks in anxiety and depression. Compassionate Mind Training (CMT), a psychological intervention focused on improving distress and wellbeing, has shown promising results in supporting depression in clinical populations. This study examined the feasibility and preliminary effects of a six-session online CMT group intervention for women in MT, with mild to moderate anxiety and/or mild to moderately severe depression.
This was a mixed-methods feasibility study. 38 participants were randomized to either CMT plus treatment as usual (TAU) or TAU alone. Feasibility and acceptability outcomes included recruitment, retention, attendance, and measure completion. Exploratory analyses examined changes in psychological outcomes. Qualitative interviews (n=16) were analyzed thematically to explore participant experiences.
Recruitment targets were met, with retention rates of 89.5% for CMT, and 73.7% for TAU. Attendance was high, and outcome measures showed 100% completion among those at follow-up. Exploratory analyses suggested improvements following CMT for depression (Patient Health Questionnaire-9, d=0.73), anxiety (Generalized Anxiety Disorder-7, d=0.53), and anxiety/depressive symptoms (Women's Health Questionnaire, d=1.12), alongside reductions in fears of compassion and self-criticism. Thematic analysis generated five themes: motivation and engagement, perceptions of trial processes, structure, support, and group experience, intervention content and skill-building, and personal outcomes, impact, and the future.
The study supports the feasibility and acceptability of CMT for women in MT. Quantitative and qualitative findings suggest potential benefits for mental health and quality of life, warranting a fully powered trial of effectiveness and cost-effectiveness.

PMID:
42412587
Bibliographic data and abstract were imported from PubMed on 08 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.